Efficacy of roxithromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: A 3-month, randomized, double-blind, placebo-controlled trial

Clinical Therapeutics

Volumn 31, Issue 8, 2009, Pages 1754-1764

  Ogrendik, Mesut ^a  

^a Nazilli State Hospital   (Turkey)

Author keywords

anaerobic bacteria; arthritis; macrolides; oral bacteria; periodontopathic bacteria; rheumatoid; roxithromycin

Indexed keywords

PLACEBO; ROXITHROMYCIN;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; NAUSEA; PATIENT ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHEUMATOID ARTHRITIS; SCORING SYSTEM; TREATMENT OUTCOME; VOMITING; XEROSTOMIA;

ADMINISTRATION, ORAL; ADULT; ANTI-BACTERIAL AGENTS; ARTHRITIS, RHEUMATOID; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; REMISSION INDUCTION; ROXITHROMYCIN; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 72149122383     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.08.014     Document Type: Article

References (50)

1. Lee D.M., and Weinblatt M.E. Rheumatoid arthritis. Lancet. 358 (2001) 903-911
2. Fries J.F., Williams C.A., Morfeld D., et al. Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies. Arthritis Rheum. 39 (1996) 616-622
3. Kässer U.R., Gleissner C., Dehne F., et al. Risk for periodontal disease in patients with longstanding rheumatoid arthritis. Arthritis Rheum. 40 (1997) 2248-2251
4. Greenwald R.A., and Kirkwood K. Adult periodontitis as a model for rheumatoid arthritis (with emphasis on treatment strategies). J Rheumatol. 26 (1999) 1650-1653
5. Mercado F.B., Marshall R.I., Klestov A.C., and Bartold P.M. Relationship between rheumatoid arthritis and periodontitis. J Periodontol 72 (2001) 779-787
6. Marotte H., Farge P., Gaudin P., et al. The association between periodontal disease and joint destruction in rheumatoid arthritis extends the link between the HLA-DR shared epitope and severity of bone destruction. Ann Rheum Dis. 65 (2006) 905-909
7. Bonfil J.J., Dillier F.L., Mercier P., et al. A "case control" study on the role of HLA DR4 in severe periodontitis and rapidly progressive periodonti-tis. Identification of types and subtypes using molecular biology (PCR.SSO). J Clin Periodontol 26 (1999) 77-84
8. Gran J.T., Husby G., and Thorsby E. The association between rheumatoid arthritis and the HLA antigen DR4. Ann Rheum Dis. 42 (1983) 292-296
9. Al-Katma M.K., Bissada N.F., Bordeaux J.M., et al. Control of periodontal infection reduces the severity of active rheumatoid arthritis. J Clin Rheumatol. 13 (2007) 134-137
10. Moen K., Brun J.G., Madland T.M., et al. Immunoglobulin G and A antibody responses to Bacteroides forsythus and Prevotella intermedia in sera and synovial fluids of arthritis patients. Clin Diagn Lab Immunol. 10 (2003) 1043-1050
11. Ogrendik M., Kokino S., Ozdemir F., et al. Serum antibodies to oral anaerobic bacteria in patients with rheumatoid arthritis. MedGenMed. 7 (2005) 2
12. Moen K., Brun J.G., Valen M., et al. Synovial inflammation in active rheumatoid arthritis and psoriatic arthritis facilitates trapping of a variety of oral bacterial DNAs. Clin Exp Rheumatol. 24 (2006) 656-663
13. Hannonen P., Möttönen T., Hakola M., and Oka M. Sulfasalazine in early rheumatoid arthritis. A 48-week double-blind, prospective, placebo-controlled study. Arthritis Rheum. 36 (1993) 1501-1509
14. O'Dell J.R., Blakely K.W., Mallek J.A., et al. Treatment of early seropositive rheumatoid arthritis: A two-year, double-blind comparison of mino-cycline and hydroxychloroquine. Arthritis Rheum. 44 (2001) 2235-2241
15. Ogrendik M., Hakguder A., and Keser N. Treatment of rheumatoid arthritis with ornidazole. A randomized, double-blind, placebo-controlled study. Rheumatology (Oxford). 45 (2006) 636-637
16. Das K.M. Sulfasalazine therapy in inflammatory bowel disease. Gastroenterol Clin North Am. 18 (1989) 1-20
17. Suresh E., Morris I.M., and Mattingly P.C. Use of minocycline in rheumatoid arthritis: A district general hospital experience. Ann Rheum Dis. 63 (2004) 1354-1355
18. Tatakis D.N., and Kumar P.S. Etiology and pathogenesis of periodontal diseases. Dent Clin North Am. 49 (2005) 491-516
19. Zalewska-Kaszubska J., and Górska D. Anti-inflammatory capabilities of macrolides. Pharmacol Res. 44 (2001) 451-454
20. Ianaro A., Ialenti A., Maffia P., et al. Anti-inflammatory activity of mac-rolide antibiotics. J Pharmacol Exp Ther. 292 (2000) 156-163
21. Lorber B. Bacteroides, Prevotella, Porphyromonas and Fusobacterium species (and other medically important anaerobic gram-negative bacilli). In: Mandell G.L., Bennett J.E., and Dolin R. (Eds). Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases. 5th ed. (2000), Churchill Livingstone, Philadelphia, Pa 2561-2570
22. Urasaki Y., Nori M., Iwata S., et al. Roxithromycin specifically inhibits development of collagen induced arthritis and production of proin-flammatory cytokines by human T cells and macrophages. J Rheumatol. 32 (2005) 1765-1774
23. Kanai K., Asano K., Hisamitsu T., and Suzaki H. Suppression of matrix me-talloproteinase production from nasal fibroblasts by macrolide antibiotics in vitro. Eur Respir J. 23 (2004) 671-678
24. Moreland L.W., Baumgartner S.W., Schiff M.H., et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 337 (1997) 141-147
25. Seymour G.J., and Gemmell E. Cytokines in periodontal disease: Where to from here?. Acta Odontol Scand. 59 (2001) 167-173
26. Yoshimura A., Hara Y., Kaneko T., and Kato I. Secretion of IL-1 beta, TNF-alpha, IL-8 and IL-1ra by human polymorphonuclear leukocytes in response to lipopolysaccharides from periodontopathic bacteria. J Periodontal Res 32 (1997) 279-286
27. Kjeldsen M., Holmstrup P., Lindemann R.A., and Bendtzen K. Bacterial-stimulated cytokine production of peripheral mononuclear cells from patients of various periodontitis categories. J Periodontol 66 (1995) 139-144
28. Rossano F., Rizzo A., Sanges M.R., et al. Human monocytes and gingival fibroblasts release tumor necrosis factor-alpha, interleukin-1 alpha and interleukin-6 in response to particulate and soluble fractions of Prevotella melaninogenica and Fusobacterium nucleatum. Int J Clin Lab Res 23 (1993) 165-168
29. Furst D.E., Saag K., Fleischmann M.R., et al. Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with metho-trexate: A six-month, double-blind, randomized, dose-ranging study. Arthritis Rheum 46 (2002) 2020-2028
30. World Medical Association. Revising the Declaration of Helsinki. Bull Med Ethics 158 (2000) 9-11
31. Arnett F.C., Edworthy S.M., Bloch D.A., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31 (1988) 315-324
32. Young D.S. Effects of drugs on clinical laboratory tests. Ann Clin Biochem 34 (1997) 579-581
33. Pincus T., Summey J.A., Soraci Jr. S.A., et al. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum 26 (1983) 1346-1353
34. Fries J.F., Spitz P.W., and Young D.Y. The dimensions of health outcomes: The health assessment question- naire, disability and pain scales. J Rheumatol 9 (1982) 789-793
35. Felson D.T., Anderson J.J., Boers M., et al., the Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 36 (1993) 729-740
36. Felson D.T., Anderson J.J., Boers M., et al., American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38 (1995) 727-735
37. Prevoo M.L., van 't Hof M.A., Kuper H.H., et al. Modified disease activity scores that include twenty-eight-joint counts: Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38 (1995) 44-48
38. How to use the DAS28 (1). http://www.das-score.nl/www.das-score.nl/howto1.htm Accessed August 22, 2005.
39. Fransen J., Creemers M.C., and Van Riel P.L. Remission in rheumatoid arthritis: Agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 43 (2004) 1252-1255
40. Vrijhoef H.J., Diederiks J.P., Spreeuwenberg C., and Van der Linden S. Applying low disease activity criteria using the DAS28 to assess stability in patients with rheumatoid arthritis. Ann Rheum Dis 62 (2003) 419-422
41. Sumbuloglu K., and Sumbuloglu V. Application of Biostatistics [in Turkish] (1991), Hatiboglu Publications, Ankara, Turkey
42. Amin A.R., Attur M.G., Thakker G.D., et al. A novel mechanism of action of tetracyclines: Effects on nitric oxide synthases. Proc Natl Acad Sci U S A 93 (1996) 14014-14019
43. Tilley B.C., Alarcón G.S., Heyse S.P., et al., MIRA Trial Group. Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. Ann Intern Med. 122 (1995) 81-89
44. Kloppenburg M., Breedveld F.C., Terwiel J.P., et al. Minocycline in active rheumatoid arthritis. A double-blind, placebo-controlled trial. Arthritis Rheum 37 (1994) 629-636
45. O'Dell J.R., Haire C.E., Palmer W., et al. Treatment of early rheumatoid arthritis with minocycline or placebo: Results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 40 (1997) 842-848
46. O'Dell J.R., Paulsen G., Haire C.E., et al. Treatment of early seropositive rheumatoid arthritis with minocycline: Four-year followup of a double-blind, placebo-controlled trial. Arthritis Rheum 42 (1999) 1691-1695
47. Greenwald R.A. Treatment of destructive arthritic disorders with MMP inhibitors. Potential role of tetracyclines. Ann N Y Acad Sci 732 (1994) 181-198
48. Greenwald R.A., Golub L.M., Lavietes B., et al. Tetracyclines inhibit human synovial collagenase in vivo and in vitro. J Rheumatol 14 (1987) 28-32
49. Greenwald R.A., Moak S.A., and Golub L.M. Low dose doxycycline inhibits pyridinoline excretion in selected patients with rheumatoid arthritis. Ann N Y Acad Sci 732 (1994) 419-421
50. Nordström D., Lindy O., Lauhio A., et al. Anti-collagenolytic mechanism of action of doxycycline treatment in rheumatoid arthritis. Rheumatol Int 17 (1998) 175-180